|
J Biol Chem, Vol. 273, Issue 26, 16426-16433, June 26, 1998
Di-leucine-mediated Internalization of Ligand by a Truncated
Growth Hormone Receptor Is Independent of the Ubiquitin Conjugation
System*
Roland
Govers,
Peter
van Kerkhof,
Alan L.
Schwartz , and
Ger J.
Strous§
From the Department of Cell Biology, Faculty of Medicine and
Institute of Biomembranes, Utrecht University, 3584 CX Utrecht, The
Netherlands and the Departments of Molecular Biology,
Pharmacology and Pediatrics, Washington University School of
Medicine, St. Louis, Missouri 63110
 |
ABSTRACT |
The growth hormone receptor (GHR) is a member of
the cytokine receptor family. Its function is to mediate cellular
responses upon binding of growth hormone. Ligand binding induces
dimerization and activation of the GHR. One mechanism by which the GHR
is rapidly inactivated involves the ubiquitin conjugation system, a
system implicated in the degradation of cytosolic and nuclear proteins. We have shown previously that the ubiquitin-conjugating system mediates
internalization of the GHR. Here, we present evidence that in addition
to the ubiquitin-dependent endocytosis signal, the
cytosolic tail of the GHR contains a di-leucine motif. Upon truncation
of the GHR at amino acid residue 349, this di-leucine motif is
activated and mediates ubiquitin-independent internalization of the
receptor. Di-leucine-mediated GHR internalization requires functional
clathrin-coated pits and results in GHR transport to the lysosome.
Although the full-length GHR internalizes independent of the di-leucine
motif, this motif may function in internalization of GHR isoforms.
 |
INTRODUCTION |
Internalization of membrane proteins may be mediated via several
amino acid sequences within the cytosolic domain (1, 2). The most
common sequences consist of short stretches of amino acids, termed
coated pit localization signals. The tyrosine-based motifs
NPXY and YXXØ (where X is any amino
acid and Ø is an amino acid with a bulky hydrophobic group) are well
known internalization motifs involved in endocytosis of many
transmembrane proteins (3). Receptors such as the LDL receptor are
endocytosed via their NPXY motif (4), while receptors such as the
transferrin receptor and the asialoglycoprotein receptor are sorted
from the plasma membrane via a YXXØ motif (5, 6). These
tyrosine-based motifs are thought to form a tight turn conformation.
Another well known endocytosis motif is the di-leucine motif.
Internalization of the insulin and 2-adrenergic receptor
is mediated by this motif (7, 8) and in case of the interleukin-6
receptor, GLUT4 and CD4, the di-leucine motif acts in cooperation with
an upstream serine (9-11). CD3 and invariant chain are internalized by a di-leucine motif and an upstream aspartic acid (12, 13). Other
endocytosis motifs have been reported as well. The amino terminus of
GLUT4 contains a FQQI internalization motif (14, 15). E-selectin
internalization is also independent of di-leucine and tyrosine-based
endocytosis motifs (16). Recently, it was shown that the attachment of
ubiquitin moieties is involved in internalization of several plasma
membrane proteins (17). Ubiquitination appears to be required for
endocytosis of Ste2p (18), Ste6p, (19) and ENaC (20).
The growth hormone receptor
(GHR)1 is a mammalian plasma
membrane protein whose internalization is mediated by the ubiquitin conjugation system (21). In particular, the Phe327 residue
within the GHR cytosolic tail is involved in both GHR ubiquitination
and ligand-induced receptor endocytosis (22, 23). However, whether the
GHR itself needs to be ubiquitinated in order to internalize ligand
remains to be elucidated. The GHR initiates the cellular actions of
growth hormone (GH) and belongs to the family of cytokine receptors
(24, 25). The GHR is a type I glycoprotein (Mr
130,000) consisting of 620 amino acid residues with a 350-cytoplasmic
residue tail, a 24-amino acid transmembrane domain, and 246 residues in
the extracellular domain containing five potential
N-glycosylation sites. The receptor has a short half-life
(26-28), and the degradation occurs within the lysosome (26). In
addition, it has been reported that the GHR is transported to the
nucleus (29), to detergent-insoluble membrane domains (30) and back to
the plasma membrane (31). GHR signaling is initiated at the plasma
membrane when two receptors are dimerized by a single GH molecule (32).
This dimerization induces recruitment and binding of the tyrosine
kinase JAK2 (33), resulting in the activation of various signal
transduction pathways (34, 35).
In the present study, we examined the internalization of GHR truncation
mutant 1-349. Although the wild-type receptor internalized in a
ubiquitin-dependent manner, this truncation mutant
internalized independent of the ubiquitin conjugation system. Further
analysis revealed that a carboxyl-terminal di-leucine motif was
responsible for internalization of truncation mutant 1-349. This
di-leucine motif mediated clathrin-dependent internalization of
the mutant, but not of the full-length wild type receptor.
 |
EXPERIMENTAL PROCEDURES |
Materials and Antisera--
Antibody (mAb5) recognizing the
luminal part of the GHR was from AGEN Inc., Parsippany, NJ. Antiserum
specific for protein-ubiquitin conjugates was a generous gift from Dr.
A. Ciechanover (Technion-Israel Institute of Technology, Haifa,
Israel). hGH was a generous gift of Lilly Research Laboratories,
Indianapolis, IN. GHR cDNA was kindly provided by Dr. William Wood,
Genentech. Culture medium, fetal bovine serum, and Geneticin were
purchased from Life Technologies, Inc.
Mutagenesis, Transfection, and Cell Culture--
The CHO cell
line CHO-ts20 (36) was used in this study. Due to a thermolabile
ubiquitin-activating enzyme (E1), the ubiquitin conjugating system is
inactive at the nonpermissive temperature of 42 °C.
CHO-ts20 cells were transfected with a pCB6 construct containing the
full-length rabbit GHR cDNA sequence using the calcium phosphate
transfection method. Truncated receptors were constructed by
introducing stop codons at various positions within the cDNA of the
rabbit GHR. For the GHR truncations 1-399, 1-349, and 1-314 without
additional mutations, polymerase chain reactions (PCRs) were performed,
using a 5'-oligonucleotide containing an NcoI restriction
site, corresponding to the NcoI site in the cDNA of the
transmembrane region of the GHR, together with 3'-oligonucleotides containing a KpnI restriction site, a stop codon, and
overlapping sequences at various positions within the cDNA,
encoding the intracellular domain of the GHR. PCR products were cut by
NcoI and KpnI and ligated into a PGEM3Z-GHR
construct. The truncated GHR cDNAs were subcloned into the CMV-NEO
expression plasmid pcDNA3 (Invitrogen).
For the other GHR truncations, PCRs were performed, using a
5'-oligonucleotide containing a PflMI site, corresponding to
the PflMI site in the cDNA of the luminal part of the
GHR and 3'-oligonucleotides containing a KpnI restriction
site, a stop codon, and overlapping sequences at various positions
within the cDNA, encoding the intracellular domain of the GHR. For
construct GHR L347,348A a 5'-oligonucleotide was used that contained
the mutations and a ClaI site, corresponding to the second
ClaI site in the cDNA of the intracellular domain of the
GHR. The 3'-oligonucleotide used for this construct overlapped cDNA
surrounding the Bsu36I site. The 5'-oligonucleotide used for
GHR construct 1-399 L347,348A contained the mutations and a
ClaI site, corresponding to the second ClaI site
in the cDNA of the intracellular domain of the GHR, while the
3'-oligonucleotide contained a KpnI restriction site, a stop
codon, and a sequence overlapping the cDNA, encoding the
intracellular domain of the GHR up to amino acid residue 399. For
construct 1-349 L347,348A a 5'-oligonucleotide was used which
contained a PflMI site, corresponding to the
PflMI site in the cDNA encoding the luminal domain of
the GHR. The 3'-oligonucleotide used for this construct contained a
KpnI restriction site, a stop codon, and a sequence
overlapping the cDNA, encoding the intracellular domain of the GHR
up to amino acid residue 349, including the appropriate mutations.
These PCR products were digested by the indicated restriction enzymes
and ligated directly into a pcDNA3-GHR construct, which was
digested by the same enzymes. All constructs were verified by in
vitro transcription-translation assays (Promega) and by
sequencing.
The cDNA constructs were transfected into CHO-ts20 cells using the
calcium phosphate transfection method. For truncations 1-399, 1-349,
and 1-314 and for GHR 1-349 L347,348A, clonal cell lines were
obtained that expressed the receptor stably. For the other mutated
receptors, cells were grown for 2 weeks in Geneticin after
transfection, whereafter the cells were used for experiments. Stable
Geneticin-resistant transfectants were grown in Eagle's minimal
essential medium (MEM- ) supplemented with 10% fetal bovine serum,
penicillin and streptomycin, and 0.45 mg/ml Geneticin. For experiments,
cells were grown in 30- or 60-mm dishes in the absence of Geneticin to
approximately 75% confluence. In the experiments described herein, 10 mM sodium butyrate was added to the cells 18 h before
use to increase GHR expression (23). Treatment of transfected CHO-ts20
cells with sodium butyrate did not alter the behavior of the GHR in any
of the parameters examined in this study.
GH Binding and Internalization--
The expression of wild-type
and mutant receptors was analyzed by binding of 125I-hGH.
125I-hGH was prepared using chloramine T (26). Cells were
grown in six-well culture dishes, washed with ice-cold
phosphate-buffered saline (PBS), and incubated for 2 h on ice with
0.2-18 nM 125I-GH in PBS containing 0.1%
bovine serum albumin, in the absence or presence of excess unlabeled
GH. After extensive washing, 1 M NaOH was added, and the
cell extracts were counted in an LKB counter. Plasma membrane
receptor numbers and binding affinities were calculated by Scatchard
analysis.
For internalization studies, cells were grown in 30-mm dishes, washed
with MEM- , supplemented with 20 mM HEPES, incubated for
1 h at 30 °C or 42 °C in MEM- /HEPES and for 0-120 min
with 8 nM 125I-GH (700,000 cpm), in the absence
or presence of excess unlabeled GH. The cells were washed three times
with ice-cold PBS, membrane-associated GH was removed by acid wash
(0.15 M NaCl, 0.05 M glycine, pH 2.5) (37), and
internalized GH was determined by measuring the radioactivity after
solubilization of the acid-treated cells by 1 M NaOH. To measure intracellular 125I-GH degradation, the incubation
medium was trichloroacetic acid-precipitated after incubation of the
cells with 125I-GH for different time periods. Briefly,
part of the incubation medium was mixed with an equal volume of 20%
ice-cold trichloroacetic acid. After incubation for 30 min on ice, the
sample was centrifuged for 10 min at 14,000 rpm at 4 °C, and the
radioactivity in the supernatant was determined.
Microscopy--
Cy3-GH was prepared using a Fluorolink-Cy3 label
kit according to the supplier's instructions (Amersham Pharmacia
Biotech). Transfected CHO cells, grown on coverslips, were incubated
for 60 min in MEM- , supplemented with 20 mM HEPES at
30 °C or at the nonpermissive temperature (42 °C) and for 60 min
with Cy3-GH (0.7 µg/ml). Cells were washed with PBS to remove unbound
label and fixed for 2 h in 3% paraformaldehyde in PBS. After
fixation, the cells were embedded in mowiol, and confocal laser
scanning microscopy was performed using a Leica TCS 4D system.
Immunoprecipitation and Western Blotting--
Cells used for
immunoprecipitations expressed wild-type GHR, GHR truncation 1-349, or
GHR 1-349 L347,348A and contained 0.98 ± 0.09 × 106, 0.96 ± 0.05 × 106, and
1.79 ± 0.15 × 106 GH binding sites at the
plasma membrane, respectively. These cells displayed the same binding
affinity for hGH.
Immunoprecipitations were performed as described previously (21).
Cells, grown in 6-cm dishes, were incubated for 1 h in MEM- ,
supplemented with 20 mM HEPES and for 15 or 30 min with 8 nM hGH. After GH incubation, cells were immediately lysed
in 0.25 ml of boiling buffer, containing 1% SDS in PBS to avoid
isopeptidase activity. After heating the lysate for 5 min at 100 °C
and shearing the DNA, immunoprecipitations were performed in 1% Triton
X-100, 0.5% SDS, 0.25% sodium deoxycholate, 0.5% bovine serum
albumin, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 2 mM Na3VO4, 20 mM NaF, 10 µg/ml leupeptin, 10 µg/ml aprotinin in PBS.
The lysate was incubated with anti-ubiquitin antiserum for 2 h on
ice. Immune complexes were isolated by the use of protein A-agarose
beads (Repligen Co., Cambridge, MA). The immunoprecipitates were washed twice with the same buffer and twice with 10-fold diluted PBS. Immune
complexes were subjected to SDS-polyacrylamide gel electrophoresis together with total cellular lysate and transferred to polyvinylidene difluoride paper. Blots were immunostained using anti-GHR (23). After
incubating the blots with rabbit anti-mouse IgG conjugated to HRP,
antigens were visualized using the ECL system (Boehringer Mannheim).
Cellular Cytosol Acidification--
Inhibition of
clathrin-mediated endocytosis by cellular cytosol acidification was
performed as described by Sandvig et al. (38). Cells were
incubated for 30 min in MEM- /HEPES and for 30 min in MEM- /HEPES
containing 20 mM NH4Cl. After washing the cells
once with 0.14 M KCl, 20 mM HEPES, 2 mM CaCl2, 1 mM MgCl2, 1 mM amiloride, 1 g/liter glucose, 0.1% BSA pH 7.0, cells
were incubated in the same buffer for 5 min, whereafter Cy3-GH or
unlabeled GH was added to the dishes. Control cells were subjected to
the same incubations, except that they were incubated in the absence of
NH4Cl. All incubation steps were performed at 30 °C.
 |
RESULTS |
Ubiquitin-independent Internalization of a GHR Truncation
Mutant--
The GHR consists of 620 amino acid residues, of which 350 residues are located intracellularly (Fig.
1). This intracellular domain contains
all of the information required for signal transduction as well as for
down-regulation. Previously, we characterized the internalization and
ubiquitination of several GHR truncation mutants (23). We showed that
GHR truncation 1-349 internalized ligand and was ubiquitinated, while
truncation mutants shorter than 314 amino acids residues were neither
ubiquitinated nor able to internalize after binding of ligand.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of the wild-type and
mutant GHRs. Hatched squares represent box1 and box2,
respectively. TM is the transmembrane domain of the GHR.
Phe327, Leu347,348, and Ala347,348
are indicated.
|
|
In the present study we examined whether the ubiquitin conjugation
system was involved in endocytosis of these GHR mutants. Therefore we
used the Chinese hamster ovary cell line CHO-ts20, which contains a
thermolabile ubiquitin-activating enzyme (E1). This
temperature-sensitive enzyme is inactive when the CHO-ts20 are
incubated at the nonpermissive temperature of 42 °C, while at
30 °C the enzyme retains its full activity. We transfected the
cDNAs of the truncation mutants into these cells and examined whether internalization of fluorescence-labeled GH via these receptors was abrogated at the nonpermissive temperature (Fig.
2A). As we have shown before
(21, 23), wild-type GHR (panels 1-620) internalized in a
ubiquitin-dependent manner. GH was internalized by the GHR at 30 °C, while the ligand remained at the plasma membrane at 42 °C, when the ubiquitin conjugation system is inactive. GHR truncations 1-600, 1-522, and 1-434 showed the same phenotype (not
shown). Internalization of these receptors was also dependent on an
intact ubiquitin-conjugating system, as was the case for GHR truncation
1-399 (Fig. 2A). GHR truncation 1-349 showed vesicular Cy3-GH staining at 30 °C as well as at 42 °C (Fig. 2A,
panels 1-349), indicating that this truncation was still
able to internalize ligand in the absence of an intact ubiquitin
conjugation system. GHR truncation 1-314 on the other hand was not
able to internalize ligand at 30 °C nor at 42 °C (Fig.
2A).

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 2.
GH internalization by wild-type and truncated
receptors in the presence or absence of an intact ubiquitin conjugation
system. A, CHO-ts20 cells expressing wild type GHR or
GHR truncations were incubated with Cy3-GH for 1 h at 30 or
42 °C. Cy3-GH was visualized by confocal microscopy.
Bar = 10 µm. B, identical cells were
incubated with 125I-GH in the absence or presence of excess
unlabeled GH for the indicated periods of time at 30 °C (solid
symbols) or 42 °C (open symbols). Specific
internalized 125I-GH was expressed as the percentage of
total cell-associated label at 90 min. C, CHO-ts20 cells
expressing the indicated GHRs were incubated with 125I-GH
in the absence or presence of excess unlabeled GH for the indicated
periods of time at 30 °C. Trichloroacetic acid-soluble radioactivity
in the incubation medium was determined and expressed as the percentage
of total cell-associated and trichloroacetic acid-soluble label at 120 min.
|
|
Quantification of ligand uptake using 125I-GH confirmed
these data (Fig. 2B). Unexpectedly, truncation of the GHR at
amino acid residue 399 increased the uptake and internalization rate of
125I-GH at 30 °C compared with the wild-type GHR.
However, at the nonpermissive temperature, internalization of ligand
was inhibited. In contrast, uptake of radiolabeled ligand by GHR
truncation 1-349 at 42 °C occurred with similar kinetics as at
30 °C, indicating ubiquitin-independent internalization. Using the
same thermosensitive CHO cells, we have demonstrated previously that
the transferrin receptor is internalized independent of the ubiquitin
conjugation system (21). Since this receptor returns to the plasma
membrane after internalization, it was tempting to speculate that GHR
truncation 1-349 was recycling. Therefore we determined the amount of
trichloroacetic acid-soluble radioactivity in the medium after
incubating the cells with 125I-GH at 30 °C (Fig.
2C). If the receptor recycled, this should not result in
degraded (trichloroacetic acid-soluble) GH in the medium, since
dissociation of ligand from the GHR does not occur at endosomal pH
(391). However, truncation 1-399 as well as truncation 1-349 showed
an increase in trichloroacetic acid-soluble radiolabel in the medium
compared with wild-type GHR (GHR 1-620). This result derives from the
increase of ligand uptake and clearly indicates that for both
truncations the ligand and receptor are sorted to lysosomes.
Clathrin-dependent and Ubiquitin-independent GHR
Internalization--
GHR truncation 1-349 internalizes independent of
the ubiquitin conjugation system. Previously, we have shown that
internalization of the wild type GHR is both
ubiquitin-dependent and clathrin-mediated (23). To examine
whether truncation 1-349 was internalized via clathrin-coated pits, we
subjected the cells to cellular cytosol acidification (Fig.
3A), which retains clathrin
lattices at the membrane but prevents coated vesicle formation. Cells
were preincubated in 20 mM NH4Cl, whereafter
they were incubated with fluorescence-labeled GH in a KCl/amiloride
buffer. This treatment inhibited ligand uptake both for the wild type
GHR (1-620) as well as for GHR truncation 1-349 (Fig. 3A,
right panels). Control incubations of the cells in the
KCl/amiloride buffer without NH4Cl preincubation did show GH internalization (Fig. 3A, left panels). This
indicates that internalization of the GHR truncated at amino acid
residue 349 is ubiquitin-independent but still dependent upon the
clathrin-mediated endocytic pathway.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of cellular cytosol acidification on
internalization and ubiquitination of wild-type GHR and GHR truncation
mutant 1-349. Cells expressing wild-type GHR or GHR truncation
1-349 were incubated in KCl/amiloride buffer after NH4Cl
preincubation (acidif) or without NH4Cl
preincubation (ctrl). A, cells were incubated for
15 min with Cy3-GH in KCl/amiloride buffer. Cy3-GH was visualized by
confocal microscopy. Bar = 10 µm. B, cells
were incubated for 15 min with or without unlabeled GH in KCl/amiloride
buffer. Ubiquitinated proteins were immunoprecipitated using an
anti-ubiquitin conjugate antiserum and Western blotted, using an
anti-GHR antibody directed against the luminal domain of the GHR. The
left lane in each panel contains total cellular lysate and
represents the receptor: upper band, mature species;
lower band, precursor species. The 25- and 40-55-kDa bands
seen in the immunoprecipitations of the right panel
originated from IgG.
|
|
We have shown previously that ubiquitination of the GHR is dependent
upon clathrin-mediated endocytosis and that GHR truncation 1-349 can
be ubiquitinated (23). Thus, we next determined whether this GHR
truncation, which does not require an intact ubiquitin conjugation
system for internalization, remains ubiquitinated upon inhibition of
the clathrin-mediated endocytic pathway. Therefore, we examined
ubiquitination of wild type GHR and GHR truncation 1-349 when
clathrin-mediated endocytosis was inhibited by cellular cytosol
acidification (Fig. 3B). Cells expressing wild-type GHR or
GHR 1-349 were preincubated for 30 min in 20 mM
NH4Cl and incubated for 5 min in a KCl/amiloride buffer and
for 15 min in a KCl/amiloride buffer with or without 8 nM
hGH. Control cells were incubated with or without 8 nM GH
in the KCl/amiloride buffer without the NH4Cl
preincubation. After the incubations, the cells were lysed, and
protein-ubiquitin conjugates were immunoprecipitated and immunoblotted (Fig. 3B). The left lane in the two panels
contains total cellular lysate and shows the apparent molecular masses
of the two receptors (130 and 75 kDa, respectively). In each panel, the
faster migrating band represents the receptor precursor and the slower
migrating band represents the mature receptor. As only a few percent of the GHR is ubiquitinated, ubiquitination of the GHR cannot be detected
in this lane, in accordance with our previous findings (21). Cell
extracts containing approximately equal amounts of GHR were used for
the anti-ubiquitin immunoprecipitation. The high molecular weight bands
visible in the upper part of these lanes represent ubiquitinated
receptors. Cells expressing wild-type GHR or GHR truncation 1-349
showed ubiquitination of the GHR, which was enhanced upon incubation of
the cells with GH. However, when clathrin-mediated internalization was
inhibited by cellular cytosol acidification, ubiquitination of both
receptors was almost completely abrogated. This effect on GHR
ubiquitination is not caused by a general inactivation of the ubiquitin
conjugation system, since cellular cytosol acidification does not
affect total cellular ubiquitination (23). These data indicate that,
while ubiquitination of GHR truncation 1-349 is not involved in
internalization, inhibition of receptor internalization results in a
marked reduction of ubiquitination of this mutant.
Characterization of Intracellular Domains Involved in
Ubiquitin-independent GHR Internalization--
To determine which
domains are involved in the ubiquitin-independent internalization of
GHR 1-349, we examined internalization of fluorescence-labeled GH by
various GHR truncation mutants (Fig. 1) in the presence (30 °C) or
absence (42 °C) of an active ubiquitin-conjugating system (Fig.
4). Cy3-GH internalization by truncations
1-399 to 1-359 was dependent upon an intact ubiquitin-conjugating
system. At 30 °C these truncations showed a vesicular pattern, but
at the nonpermissive temperature Cy3-GH remained at the plasma
membrane. This indicated that amino acid residues 350-359 restored the
ubiquitin-dependent internalization of the GHR.
Ubiquitin-dependent GHR internalization was also restored
by truncation of the receptor at amino acid residue 346, suggesting
that the amino acid residues 347, 348, and 349 were involved in the
ubiquitin-independent internalization of GHR truncation 1-349. Since
this amino acid residue triplet comprised two sequential leucine
residues and a serine residue, it likely represented a di-leucine
endocytosis motif, responsible for ubiquitin-independent GHR
internalization when the receptor was truncated at amino acid residue
349. The full-length receptor, however, was internalized only when the
ubiquitin conjugation system is active, indicating that the di-leucine
motif at position 347-348 was not an active endocytosis signal in the
full-length GHR. GHR truncation mutants shorter than 330 amino acid
residues did not internalize ligand at 30 °C nor at 42 °C. This
finding demonstrated that the ubiquitin-dependent
endocytosis motif was located upstream of amino acid residue 334. For
these experiments we used a mixed culture of stable transfectants, of
which only a small percentage expressed the GHR to a considerable
extent. Therefore, we were unable to determine whether these GHRs were ubiquitinated. We expect that GHR truncation 1-334 was ubiquitinated, while the internalization-deficient truncation 1-330 was not
ubiquitinated.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 4.
Internalization of Cy3-GH by GHR truncation
mutants in the presence or absence of an intact ubiquitin conjugation
system. CHO-ts20 cells expressing the indicated GHR truncation
mutants were incubated with Cy3-GH for 1 h at 30 or 42 °C.
Cy3-GH was visualized by confocal microscopy. Bar = 10 µm.
|
|
Involvement of Di-leucine Motif in GHR Internalization and
Ubiquitination--
To investigate the role of the di-leucine motif at
position 347-348 in internalization of the wild-type GHR, we mutated
this leucine doublet in the full-length receptor cDNA and in the
cDNA encoding the GHR truncation mutants 1-399 and 1-349 (Fig.
1). We transfected the cDNAs into the CHO-ts20 cells and studied
the uptake of Cy3-GH (Fig.
5A). Mutating the leucine
doublet in the full-length receptor did not influence internalization
of Cy3-GH (panels 1-620 L347,348A). The same was
observed when the leucine doublet was mutated in GHR truncation 1-399
(panels 1-399 L347,348A). As expected, mutating the leucine
doublet in GHR 1-349 restored the ubiquitin-dependent
ligand internalization (panels 1-349 L347,348A).

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of mutations L347,348A on
internalization and ubiquitination of wild type GHR and GHR truncation
mutants 1-399 and 1-349. A, CHO-ts20 cells expressing
the indicated GHR were incubated with Cy3-GH for 1 h at 30 or
42 °C. Cy3-GH was visualized by confocal microscopy.
Bar = 10 µm. B, CHO-ts20 cells expressing
the indicated GHR and untransfected cells (ts20) were incubated for 30 min with or without unlabeled GH. Ubiquitinated proteins were
immunoprecipitated using an anti-ubiquitin conjugate antiserum and
Western blotted using an anti-GHR antibody directed against the luminal
domain of the GHR. The left lane in each panel contains
total cellular lysate and represents the receptor: upper
band, mature species; lower band, precursor species.
The 40-55-kDa bands seen in the immunoprecipitations originated from
IgG.
|
|
Having established that GHR truncation 1-349 is internalized by a
di-leucine motif, which acts independent of the ubiquitin conjugation
system, we investigated the role of this di-leucine motif on GHR
ubiquitination (Fig. 5B). Cells expressing the indicated receptors and untransfected cells (ts20) were incubated in the absence
or presence of 8 nM GH for 30 min at 30 °C. The cells were lysed, and protein-ubiquitin conjugates were immunoprecipitated. The immunoprecipitates and the total cellular lysates were analyzed as
described for Fig. 3. The high molecular weight bands in the upper part
of these lanes represent ubiquitinated receptors. Untransfected cells
(ts20) showed no (ubiquitinated) receptor. Wild-type as well as mutant
receptors showed ubiquitination. The amount of ubiquitinated GHR in the
absence of ligand varied between experiments as can be seen in Figs. 3
and 5. In general, GH-induced ubiquitination of truncation 1-349 did
not differ much from basal (non-GH-induced) receptor ubiquitination.
Presuming that GHR ubiquitination is a plasma membrane event, the time
for GH-induced ubiquitination of GHR 1-349 might be limited, since
this mutant internalizes at an increased rate (Fig. 2B),
resulting in a reduced GH-dependent receptor
ubiquitination. The molecular weight of the ubiquitinated truncations
1-349 and 1-349 L347,348A is significantly lower than the molecular
weight of the ubiquitinated wild type receptor (1-620), partly due to
a decreased amount of ubiquitination. Interestingly, the amount of
ubiquitin conjugated to the mutated truncation (1-349 L347,348A) does
not differ appreciably from the amount of ubiquitin on GHR truncation
1-349 with the intact di-leucine motif. Therefore we conclude that the
di-leucine motif affects GHR internalization but not GHR
ubiquitination.
 |
DISCUSSION |
The ubiquitin conjugation system has an important function in many
regulatory processes within the cell (for review see Hershko and
Ciechanover (39)). The way by which the ubiquitin conjugation system
acts on the vast majority of these processes is thought to be via the
targeting of regulatory proteins for degradation by the proteasome.
Therefore, a regulatory protein becomes polyubiquitinated by specific
enzymes catalyzing a cascade of reactions leading to the covalent
attachment of ubiquitin to free -amino groups within the protein.
The 26 S proteasome recognizes the polyubiquitin chains on the
substrate and degrades the protein, thereby releasing free ubiquitin
molecules, which can enter a new ubiquitin cycle. Ubiquitin conjugation
has been implicated in the degradation of many regulatory proteins,
such as cyclins (40, 41), I B (42), p53 (43), Eps15 (44), and
STAT1 (45). Recent studies have indicated that ubiquitin is a key
player in several endocytic events (46, 47). Leung et al.
showed that the GHR is ubiquitinated in rabbit liver (48). We have
shown that the ubiquitin conjugation system is required for GH-induced
internalization (down-regulation) of the GHR (21) and that
ubiquitination of the GHR itself is linked to ligand-mediated GHR
endocytosis (23). Furthermore, Hicke and Riezman (18) demonstrated that
ligand-stimulated Ste2p endocytosis in yeast is preceded by Ste2p
ubiquitination. For several plasma membrane proteins it has been
suggested that ubiquitination is involved in (partial) degradation by
the proteasome (49-51).
In the present study we show that truncation of the GHR at amino acid
residue 349 results in a receptor which is capable of internalizing
ligand independent of the ubiquitin-conjugating system. This GHR
truncation mutant is able to internalize ligand at the nonpermissive
temperature in the CHO-ts20 cell line, which contains a
temperature-sensitive ubiquitin-activating enzyme (E1) (36). Using this
cellular system, we previously showed that the recycling transferrin
receptor is internalized independent of the ubiquitin conjugation
system (21). Our present data indicate that GH internalized by GHR
truncation 1-349 is degraded in the lysosome. Since dissociation of
ligand from the GHR requires a low pH (28), we conclude that the GHR
truncation mutant itself is also transported to the lysosome. Moreover,
we found that GHR truncation mutant 1-349 is internalized via the
clathrin-mediated endocytic pathway as is the wild type GHR. Although
GHR truncation 1-349 is internalized independent of the
ubiquitin-conjugating system, this receptor is still ubiquitinated.
Apparently, ubiquitination of this truncation mutant serves no
function, although ubiquitination still depends upon clathrin-mediated
endocytosis.
Using various GHR mutants we show that the ubiquitin-independent
internalization of GHR truncation 1-349 is mediated by a di-leucine
motif at the carboxyl-terminal end of the truncation (positions 347 and
348). This motif is known to be involved in internalization of many
membrane proteins (2). Recently, it was shown that a di-leucine motif
mediates internalization of the interleukin-6 receptor, another member
of the cytokine receptor family (9). Since mutating the di-leucine
motif in the full-length GHR did not inhibit internalization, the
di-leucine motif has no apparent function in endocytosis of the wild
type GHR. Mutating the di-leucine motif in truncation 1-349 restored
the ubiquitin-dependent internalization, most probably
mediated via a motif containing Phe-327 (23).
Ubiquitin-dependent internalization was also restored by
truncating the receptor only 10 amino acid residues behind residue 349. This indicates that amino acid residues 350 to 359 inhibit receptor
internalization by the di-leucine motif, probably by masking this
motif. Truncating the GHR between amino acid residues 334 and 346 resulted in ubiquitin-dependent internalization of the GHR
and indicates that the ubiquitin-dependent internalization motif is located between amino acid residues 271 and 334. Moreover, the
last four amino acid residues in this region are likely part of the
ubiquitin-dependent internalization signal together with Phe327. At present, we cannot exclude that additional amino
acid residues between residues 271 and 334 are needed for GHR
internalization. Furthermore, the DSGRTS sequence between amino acid
residue 365 and 370 does not seem to represent a ubiquitination domain,
although a DSGXXS motif has been implicated in
ubiquitination of -catenin and I B (52, 53). Previously, we
have shown that GHR truncation mutant 1-314 is neither internalized
nor ubiquitinated (23). Since Lys-315 is the only lysine residue
between amino acid residues 314 and 334, this particular lysine might
be involved in both of these processes.
Our data show that truncation of the GHR at amino acid residue 349 activates a ubiquitin-independent di-leucine internalization motif.
This motif is extremely well conserved within the GHRs of different
species (54) and is identical to the DXXXLL internalization motif found in CD3 (12). Internalization of receptor truncation 1-349 may be mediated by a ubiquitin-dependent mechanism
as well as by a ubiquitin-independent mechanism, while the full-length receptor is internalized exclusively by the
ubiquitin-dependent mechanism. The physiological role of
the di-leucine motif is thus not yet clear. It may well be that, under
certain conditions, the GHR di-leucine motif is activated due to
conformational changes within or partial degradation of the GHR.
Alternatively, the di-leucine motif may be functional in a GHR isoform,
as many receptors are present as alternative spliced isoforms that
differ in their COOH-terminal intracellular domains (e.g. G
protein-coupled 5-HT7 receptor (55), dopamine
D2 receptor (56), angiotensin II receptor (57), tyrosine kinase receptor TrkB (58)). Several GHR isoforms have been described. One lacks exon 3, resulting in a 22-amino acid deletion in the extracellular domain of the receptor (59). Two GHR isoforms have an
intracellular domain of only 7 and 9 amino acid residues (60, 61).
Other GHR isoforms have been located within the brain (e.g.
the choroid plexus (62, 63)) and liver (64, 65). Whether any of these
GHR isoforms is internalized via the di-leucine motif remains to be
determined. Finally, ubiquitin itself or associated proteins may
possess structural elements, which mimic the di-leucine motif, such
that a common feature underlies these two apparently independent
internalization signals.
 |
ACKNOWLEDGEMENTS |
We thank Dr. William Wood for kindly
providing the GHR cDNA and Eli Lilly Research Laboratories for
their kind gift of hGH.
 |
FOOTNOTES |
*
This work was supported by Grants NWO-902-23-188 and
NWO-902-68-244 from the Netherlands Organization for Scientific
Research, by European Union Network Grant ERBFMRXCT96-0026, and by the
National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Dept. of Cell Biology,
Faculty of Medicine, Institute of Biomembranes, Utrecht University
Heidelberglaan 100, AZU H02.314 3584 CX Utrecht, The Netherlands. Tel.:
31-30-2506476; Fax: 31-30-2541797; E-mail: strous{at}med.uu.nl.
1
The abbreviations used are: GHR, growth hormone
receptor; CHO, Chinese hamster ovary; PCR, polymerase chain reaction;
MEM- , Eagle's minimal essential medium; PBS, phosphate-buffered
saline.
 |
REFERENCES |
-
Trowbridge, I. S.
(1991)
Curr. Opin. Cell Biol.
3,
634-641[CrossRef][Medline]
[Order article via Infotrieve]
-
Mellman, I.
(1996)
Annu. Rev. Cell Dev. Biol.
12,
575-625[CrossRef][Medline]
[Order article via Infotrieve]
-
Marks, M. S.,
Ohno, H.,
Kirchhausen, T.,
and Bonifacino, J. S.
(1997)
Trends Cell Biol.
7,
124-128[CrossRef][Medline]
[Order article via Infotrieve]
-
Chen, W. J.,
Goldstein, J. L.,
and Brown, M. S.
(1990)
J. Biol. Chem.
265,
3116-3123[Abstract/Free Full Text]
-
Collawn, J. F.,
Stangel, M.,
Kuhn, L. A.,
Esekogwu, V.,
and Jing, S. Q.
(1990)
Cell
63,
1061-1072[CrossRef][Medline]
[Order article via Infotrieve]
-
Spiess, M.
(1990)
Biochemistry
29,
10009-10018[CrossRef][Medline]
[Order article via Infotrieve]
-
Haft, C. R.,
Klausner, R. D.,
and Taylor, S. I.
(1994)
J. Biol. Chem.
269,
26286-26294[Abstract/Free Full Text]
-
Gabilondo, A. M.,
Hegler, J.,
Krasel, C.,
Boivinjahns, V.,
Hein, L.,
and Lohse, M. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12285-12290[Abstract/Free Full Text]
-
Dittrich, E.,
Haft, C. R.,
Muys, L.,
Heinrich, P. C.,
and Graeve, L.
(1996)
J. Biol. Chem.
271,
5487-5494[Abstract/Free Full Text]
-
Garippa, R. J.,
Johnson, A.,
Park, J.,
Petrush, R. L.,
and McGraw, T., E.
(1996)
J. Biol. Chem.
271,
20660-20668[Abstract/Free Full Text]
-
Shin, J.,
Dunbrack, R. L., Jr.,
Lee, S.,
and Strominger, J. L.
(1991)
J. Biol. Chem.
266,
10658-10665[Abstract/Free Full Text]
-
Dietrich, J.,
Kastrup, J.,
Nielsen, B. L.,
Odum, N.,
and Geisler, C.
(1997)
J. Cell Biol.
138,
271-281[Abstract/Free Full Text]
-
Pond, L.,
Kuhn, L., A.,
Teyton, L.,
Schutze, M.-P.,
Tainer, J. A.,
Jackson, M. R.,
and Peterson, P. A.
(1995)
J. Biol. Chem.
270,
19989-19997[Abstract/Free Full Text]
-
Piper, R. C.,
Tai, C.,
Kulesza, P.,
Pang, S.,
Warnock, D.,
Baenziger, J.,
Slot, J. W.,
Geuze, H. J.,
Puri, C.,
and James, D. E.
(1993)
J. Cell Biol.
121,
1221-1232[Abstract/Free Full Text]
-
Garippa, R. J.,
Judge, T. W.,
James, D. E.,
and McGraw, T. E.
(1994)
J. Cell Biol.
124,
705-715[Abstract/Free Full Text]
-
Chuang, P. I.,
Young, B. A.,
Thiagarajan, R. R.,
Cornejo, C.,
Winn, R. K.,
and Harlan, J. M.
(1997)
J. Biol. Chem.
272,
24813-24818[Abstract/Free Full Text]
-
Hicke, L.
(1997)
FASEB J.
11,
1215-1226[Abstract]
-
Hicke, L.,
and Riezman, H.
(1996)
Cell
84,
277-287[CrossRef][Medline]
[Order article via Infotrieve]
-
Kolling, R.,
and Hollenberg, C. P.
(1994)
EMBO J.
13,
3261-3271[Medline]
[Order article via Infotrieve]
-
Staub, O.,
Dho, S.,
Henry, P., C.,
Correa, J.,
Ishikawa, T.,
McGlade, J.,
and Rotin, D.
(1996)
EMBO J.
15,
2371-2380[Medline]
[Order article via Infotrieve]
-
Strous, G. J.,
van Kerkhof, P.,
Govers, R.,
Ciechanover, A.,
and Schwartz, A. L.
(1996)
EMBO J.
15,
3806-3812[Medline]
[Order article via Infotrieve]
-
Allevato, G.,
Billestrup, N.,
Goujon, L.,
Galsgaard, E. D.,
Norstedt, G.,
Postel- Vinay, M.-C.,
Kelly, P. A.,
and Nielsen, J. H.
(1995)
J. Biol. Chem.
270,
17210-17214[Abstract/Free Full Text]
-
Govers, R.,
van Kerkhof, P.,
Schwartz, A. L.,
and Strous, G. J.
(1997)
EMBO J.
16,
4851-4858[CrossRef][Medline]
[Order article via Infotrieve]
-
Finidori, J.,
and Kelly, P. A.
(1995)
J. Endocrinol.
147,
11-23[Abstract/Free Full Text]
-
Ihle, J. N.
(1995)
Nature
377,
591-594[CrossRef][Medline]
[Order article via Infotrieve]
-
Murphy, L. J.,
and Lazarus, L.
(1984)
Endocrinology
115,
1625-1632[Abstract/Free Full Text]
-
Baxter, R. C.
(1985)
Endocrinology
117,
650-655[Abstract/Free Full Text]
-
Roupas, P.,
and Herington, A. C.
(1988)
Mol. Cell. Endocrinol.
57,
93-99[CrossRef][Medline]
[Order article via Infotrieve]
-
Lobie, P. E.,
Mertani, H.,
Morel, G.,
Morales-Bustos, O.,
Norstedt, G.,
and Waters, M. J.
(1994)
J. Biol. Chem.
269,
21330-21339[Abstract/Free Full Text]
-
Goldsmith, J. F.,
Lee, S. J.,
Jiang, J.,
and Frank, S. J.
(1997)
Am. J. Physiol.
36,
E932-E941
-
Ilondo, M. M.,
Vanderschueren Lodeweyckx, M.,
Courtoy, P. J.,
and de Meyts, P.
(1992)
Endocrinology
130,
2037-2044[Abstract/Free Full Text]
-
Cunningham, B. C.,
Ultsch, M.,
De Vos, A. M.,
Mulkerrin, M. G.,
Clauser, K. R.,
and Wells, J. A.
(1991)
Science
254,
821-825[Abstract/Free Full Text]
-
Argetsinger, L. S.,
Campbell, G. S.,
Yang, X.,
Witthuhn, B. A.,
Silvennoinen, O.,
Ihle, J. N.,
and Carter Su, C.
(1993)
Cell
74,
237-244[CrossRef][Medline]
[Order article via Infotrieve]
-
Argetsinger, L. S.,
and Cartersu, C.
(1996)
Physiol. Rev.
76,
1089-1107[Abstract/Free Full Text]
-
Carter Su, C.,
Schwartz, J.,
and Smit, L. S.
(1996)
Annu. Rev. Physiol.
58,
187-207[CrossRef][Medline]
[Order article via Infotrieve]
-
Kulka, R. G.,
Raboy, B.,
Schuster, R.,
Parag, H. A.,
Diamond, G.,
Ciechanover, A.,
and Marcus, M.
(1988)
J. Biol. Chem.
263,
15726-15731[Abstract/Free Full Text]
-
Roupas, P.,
and Herington, A. C.
(1986)
Mol. Cell. Endocrinol.
47,
81-90[CrossRef][Medline]
[Order article via Infotrieve]
-
Sandvig, K.,
Olsnes, S.,
Petersen, O., W.,
and van Deurs, B.
(1987)
J. Cell Biol.
105,
679-689[Abstract/Free Full Text]
-
Hershko, A., and Ciechanover, A. (1998) Annu. Rev. Biochem.,
67, in press
-
Glotzer, M.,
Murray, A. W.,
and Kirschner, M. W.
(1991)
Nature
349,
132-138[CrossRef][Medline]
[Order article via Infotrieve]
-
Murray, A.
(1995)
Cell
81,
149-152[CrossRef][Medline]
[Order article via Infotrieve]
-
Alkalay, I.,
Yaron, A.,
Hatzubai, A.,
Orian, A.,
Ciechanover, A.,
and Benneriah, Y.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10599-10603[Abstract/Free Full Text]
-
Maki, C. G.,
Huibregtse, J. M.,
and Howley, P. M.
(1996)
Cancer Res.
56,
2649-2654[Abstract/Free Full Text]
-
van Delft, S.,
Govers, R.,
Strous, G. J.,
Verkleij, A. J.,
and van Bergen en Henegouwen, P. M. P.
(1997)
J. Biol. Chem.
272,
14013-14016[Abstract/Free Full Text]
-
Kim, T. K.,
and Maniatis, T.
(1996)
Science
273,
1717-1719[Abstract/Free Full Text]
-
Galan, J. M.,
Moreau, V.,
Andre, B.,
Volland, C.,
and Haguenauer-Tsapis, R.
(1996)
J. Biol. Chem.
271,
10946-10952[Abstract/Free Full Text]
-
Egner, R.,
and Kuchler, K.
(1996)
FEBS Lett.
378,
177-181[CrossRef][Medline]
[Order article via Infotrieve]
-
Leung, D. W.,
Spencer, S. A.,
Cachianes, G.,
Hammonds, R. G.,
Collins, C.,
Henzel, W. J.,
Barnard, R.,
Waters, M. J.,
and Wood, W. I.
(1987)
Nature
330,
537-543[CrossRef][Medline]
[Order article via Infotrieve]
-
Mimnaugh, E. G.,
Chavany, C.,
and Neckers, L.
(1996)
J. Biol. Chem.
271,
22796-22801[Abstract/Free Full Text]
-
Mori, S.,
Tanaka, K.,
Omura, S.,
and Saito, Y.
(1995)
J. Biol. Chem.
270,
29447-29452[Abstract/Free Full Text]
-
Jeffers, M.,
Taylor, G. A.,
Weidner, K. M.,
Omura, S.,
and Vandewoude, G. F.
(1997)
Mol. Cell. Biol.
17,
799-808[Abstract]
-
Aberle, H.,
Bauer, A.,
Stappert, J.,
Kispert, A.,
and Kemler, R.
(1997)
EMBO J.
16,
3797-3804[CrossRef][Medline]
[Order article via Infotrieve]
-
Chen, Z.,
Hagler, J.,
Palombella, V. J.,
Melandri, F.,
Scherer, D.,
Ballard, D.,
and Maniatis, T.
(1995)
Genes Dev.
9,
1586-1597[Abstract/Free Full Text]
-
Kelly, P. A.,
Ali, S.,
Rozakis, M.,
Goujon, L.,
Nagano, M.,
Pellegrini, I.,
Gould, D.,
Djiane, J.,
Edery, M.,
Finidori, J.,
et al..
(1993)
Recent Prog. Horm. Res.
48,
123-164
-
Heidmann, D. E.,
Metcalf, M. A.,
Kohen, R.,
and Hamblin, M. W.
(1997)
J. Neurochem.
68,
1372-1381[Medline]
[Order article via Infotrieve]
-
Fishburn, C. S.,
Elazar, Z.,
and Fuchs, S.
(1995)
J. Biol. Chem.
270,
29819-29824[Abstract/Free Full Text]
-
Curnow, K. M.,
Pascoe, L.,
Davies, E.,
White, P. C.,
Corvol, P.,
and Clauser, E.
(1995)
Mol. Endocrinol.
9,
1250-1262[Abstract/Free Full Text]
-
Baxter, G. T.,
Radeke, M. J.,
Kuo, R. C.,
Makrides, V.,
Hinkle, B.,
Hoang, R.,
Coit, D.,
Valenzuela, P.,
and Feinstein, S. C.
(1997)
J. Neurosci.
17,
2683-2690[Abstract/Free Full Text]
-
Urbanek, M.,
MacLeod, J. N.,
Cooke, N. E.,
and Liebhaber, S. A.
(1992)
Mol. Endocrinol.
6,
279-287[Abstract/Free Full Text]
-
Dastot, F.,
Sobrier, M. L.,
Duquesnoy, P.,
Duriez, B.,
Goossens, M.,
and Amselem, S.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10723-10728[Abstract/Free Full Text]
-
Ross, R. J.,
Esposito, N.,
Shen, X. Y.,
Von Laue, S.,
Chew, S. L.,
Dobson, P. R.,
and Finidori, J.
(1997)
Mol. Endocrinol.
11,
265-273[Abstract/Free Full Text]
-
Lai, Z.,
Emtner, M.,
Roos, P.,
and Nyberg, F.
(1991)
Brain Res.
546,
222-226[CrossRef][Medline]
[Order article via Infotrieve]
-
Lai, Z.,
Roos, P.,
Zhai, Q.,
Olsson, Y.,
Fholenhag, K.,
Larsson, C.,
and Nyberg, F.
(1993)
Brain Res.
621,
260-266[CrossRef][Medline]
[Order article via Infotrieve]
-
Hocquette, J. F.,
Postel-Vinay, M. C.,
Kayser, C.,
de Hemptinne, B.,
and Amar Costesec, A.
(1989)
Endocrinology
125,
2167-2174[Abstract/Free Full Text]
-
Delehaye Zervas, M. C.,
Mertani, H.,
Martini, J. F.,
Nihoul Fekete, C.,
Morel, G.,
and Postel-Vinay, M. C.
(1994)
J. Clin. Endocrinol. Metab.
78,
1473-1480[Abstract]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Tanaka, N. Tanaka, Y. Saeki, K. Tanaka, M. Murakami, T. Hirano, N. Ishii, and K. Sugamura
c-Cbl-Dependent Monoubiquitination and Lysosomal Degradation of gp130
Mol. Cell. Biol.,
August 1, 2008;
28(15):
4805 - 4818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Chen, X. Wang, J. Ben, S. Yue, H. Bai, X. Guan, X. Bai, L. Jiang, Y. Ji, L. Fan, et al.
The Di-Leucine Motif Contributes to Class A Scavenger Receptor-Mediated Internalization of Acetylated Lipoproteins
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2006;
26(6):
1317 - 1322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Staub and D. Rotin
Role of Ubiquitylation in Cellular Membrane Transport
Physiol Rev,
April 1, 2006;
86(2):
669 - 707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Flores-Morales, C. J. Greenhalgh, G. Norstedt, and E. Rico-Bautista
Negative Regulation of Growth Hormone Receptor Signaling
Mol. Endocrinol.,
February 1, 2006;
20(2):
241 - 253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, K. G. Suresh Kumar, W. Tang, V. S. Spiegelman, and S. Y. Fuchs
Negative Regulation of Prolactin Receptor Stability and Signaling Mediated by SCF{beta}-TrCP E3 Ubiquitin Ligase
Mol. Cell. Biol.,
May 1, 2004;
24(9):
4038 - 4048.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. Muller, J. J. Kopchick, A. Flyvbjerg, and A. J. van der Lely
Growth Hormone Receptor Antagonists
J. Clin. Endocrinol. Metab.,
April 1, 2004;
89(4):
1503 - 1511.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Pasquali, M.-L. Curchod, S. Walchli, X. Espanel, M. Guerrier, F. Arigoni, G. Strous, and R. H. van Huijsduijnen
Identification of Protein Tyrosine Phosphatases with Specificity for the Ligand-Activated Growth Hormone Receptor
Mol. Endocrinol.,
November 1, 2003;
17(11):
2228 - 2239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. C. Mertani, M. Raccurt, A. Abbate, J. Kindblom, J. Tornell, N. Billestrup, Y. Usson, G. Morel, and P. E. Lobie
Nuclear Translocation and Retention of Growth Hormone
Endocrinology,
July 1, 2003;
144(7):
3182 - 3195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. D. Dahlen, V. C. Broudy, and J. G. Drachman
Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs
Blood,
July 1, 2003;
102(1):
102 - 108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Lu, P. Scott, G. J. Strous, and L. A. Schuler
Multiple Internalization Motifs Differentially Used by Prolactin Receptor Isoforms Mediate Similar Endocytic Pathways
Mol. Endocrinol.,
November 1, 2002;
16(11):
2515 - 2527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Kopchick, C. Parkinson, E. C. Stevens, and P. J. Trainer
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
Endocr. Rev.,
October 1, 2002;
23(5):
623 - 646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gent, P. van Kerkhof, M. Roza, G. Bu, and G. J. Strous
Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis
PNAS,
July 23, 2002;
99(15):
9858 - 9863.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. van Kerkhof, C. M. A. dos Santos, M. Sachse, J. Klumperman, G. Bu, and G. J. Strous
Proteasome Inhibitors Block a Late Step in Lysosomal Transport of Selected Membrane but not Soluble Proteins
Mol. Biol. Cell,
August 1, 2001;
12(8):
2556 - 2566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kawakami, J. Taguchi, T. Murata, and R. K. Puri
The interleukin-13 receptor {alpha}2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway
Blood,
May 1, 2001;
97(9):
2673 - 2679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sachse, P. van Kerkhof, G. J. Strous, and J. Klumperman
The ubiquitin-dependent endocytosis motif is required for efficient incorporation of growth hormone receptor in clathrin-coated pits, but not clathrin-coated lattices
J. Cell Sci.,
January 11, 2001;
114(21):
3943 - 3952.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. van Kerkhof, R. Govers, C. M. Alves dos Santos, and G. J. Strous
Endocytosis and Degradation of the Growth Hormone Receptor Are Proteasome-dependent
J. Biol. Chem.,
January 21, 2000;
275(3):
1575 - 1580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nakamura and M. Ascoli
A Dileucine-Based Motif in the C-Terminal Tail of the Lutropin/Choriogonadotropin Receptor Inhibits Endocytosis of the Agonist-Receptor Complex
Mol. Pharmacol.,
October 1, 1999;
56(4):
728 - 736.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Maamra, J. Finidori, S. Von Laue, S. Simon, S. Justice, J. Webster, S. Dower, and R. Ross
Studies with a Growth Hormone Antagonist and Dual-fluorescent Confocal Microscopy Demonstrate that the Full-length Human Growth Hormone Receptor, but Not the Truncated Isoform, Is Very Rapidly Internalized Independent of Jak2-Stat5 Signaling
J. Biol. Chem.,
May 21, 1999;
274(21):
14791 - 14798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Strous and R Govers
The ubiquitin-proteasome system and endocytosis
J. Cell Sci.,
January 5, 1999;
112(10):
1417 - 1423.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhang, T. Willson, D. Metcalf, D. Cary, D. J. Hilton, R. Clark, and N. A. Nicola
The Box-1 Region of the Leukemia Inhibitory Factor Receptor alpha -Chain Cytoplasmic Domain Is Sufficient for Hemopoietic Cell Proliferation and Differentiation
J. Biol. Chem.,
December 18, 1998;
273(51):
34370 - 34383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, M. Paz Marzolo, P. van Kerkhof, G. J. Strous, and G. Bu
The YXXL Motif, but Not the Two NPXY Motifs, Serves as the Dominant Endocytosis Signal for Low Density Lipoprotein Receptor-related Protein
J. Biol. Chem.,
May 26, 2000;
275(22):
17187 - 17194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kawakami, F. Takeshita, and R. K. Puri
Identification of Distinct Roles for a Dileucine and a Tyrosine Internalization Motif in the Interleukin (IL)-13 Binding Component IL-13 Receptor alpha 2 Chain
J. Biol. Chem.,
June 29, 2001;
276(27):
25114 - 25120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sachse, S. Urbe, V. Oorschot, G. J. Strous, and J. Klumperman
Bilayered Clathrin Coats on Endosomal Vacuoles Are Involved in Protein Sorting toward Lysosomes
Mol. Biol. Cell,
April 1, 2002;
13(4):
1313 - 1328.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|